FDA inspection
Bayer AG: FDA inspection ending Mar 20, 2002
FDA inspection 208001 · Voluntary Action Indicated (VAI) · Leverkusen
Key facts
| Inspection ID | 208001 |
|---|---|
| Firm | Bayer AG |
| FEI number | 3002806462 |
| Address | Bayer Ag, Gebaude Q 26 |
| City | Leverkusen |
| Fiscal year | 2002 |
| Inspection end date | Mar 20, 2002 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data